Gateway for:

Member Countries

Phago-immunotherapy of anthrax

#2981.2


Complex Therapy and Prophylaxis of Anthrax Infection with Specific Bacteriophages and Immunoglobulins

Tech Area / Field

  • MED-OTH/Other/Medicine
  • BIO-CGM/Cytology, Genetics and Molecular Biology/Biotechnology
  • BIO-MIB/Microbiology/Biotechnology

Status
8 Project completed

Registration date
07.12.2005

Completion date
18.04.2012

Senior Project Manager
Melnikov V G

Leading Institute
Institute of Immunological Engineering, Russia, Moscow reg., Lyubuchany

Collaborators

  • Laval University, Canada, QC, Quebec City

Project summary

Anthrax is a dangerous infection whose development is fast and severe. Russian and foreign researchers consider the current epidemiological situation on anthrax as being rather complicated and far from stabilization. Antibiotics remain common drugs that are used for therapy of anthrax. The occurrence of antibiotic-resistant strains of B.Anthracis is often reported. Besides, antibiotics are not always effective against severe septic forms of the infection. In our view, a promising approach to resolving this problem is to develop a therapeutic formulation on the basis of bacterial phages lytic for B. Anthracis.

A distinguished feature of B. anthracis is that the pathogen carries factors of pathogenicity (toxins and capsules), inhibition of which does not occur in the presence of phages. Therefore, it is impossible to resolve the problem of prophylaxis and cure of anthrax by applying phage formulations only.

A possible direction of the research may be the production of monoclonal antibodies with pre-set specificity to certain antigens of B.Anthracis depending on the growth of microbes. Therefore, the application of complex formulations based on bacterial phages and antibodies could be one of promising solutions of the problem of therapy and prophylaxis of B.Anthrax infection.


Back